悦康药业公告，公司控股股东阜阳京悦永顺信息咨询有限公司所持的172万股股票将被北京市第二中级 人民法院进行司法拍卖。本次拍卖时间为2026年3月16日10时至2026年3月17日10时止，起拍价为 4017.06万元，保证金为800万元，增价幅度为20万元。此次拍卖不会影响公司控制权稳定，也不会对公 司日常经营管理造成影响。 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

Core Viewpoint - The announcement details the resignation of two key personnel at Yuyuan Pharmaceutical Group Co., Ltd., including the election of a new employee representative director, ensuring compliance with legal regulations and maintaining board functionality [1][3]. Group 1: Resignation of Directors and Senior Management - Zhang Wei, the employee representative director, resigned for personal reasons but will remain with the company [1]. - Yang Lei, the deputy general manager, resigned due to work adjustments but will also continue to work at the company [1]. - Both resignations will not affect the normal operations of the company, as they have completed the necessary handover procedures [2]. Group 2: Election of Employee Representative Director - On February 13, 2026, Yang Lei was elected as the employee representative director for the third board of directors, with a term lasting until the end of the current board's term [3]. - Yang Lei meets all qualifications and conditions required by relevant laws and the company's articles of association to serve as a director [3]. - The number of directors who are also senior management and employee representative directors does not exceed half of the total board members, complying with legal and regulatory requirements [3].

证券代码：688658 证券简称：悦康药业 公告编号：2026-005 2026 年 2 月 13 日，公司召开了职工代表大会，选举杨磊先生为公司第三届 董事会职工代表董事，任期自 2026 年 2 月 13 日起至第三届董事会任期届满之日 止。 悦康药业集团股份有限公司 关于公司董事、高级管理人员离任 暨补选职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 悦康药业集团股份有限公司（以下简称"公司"）董事会于近日收到公司职 工代表董事张伟先生、副总经理杨磊先生递交的书面辞任报告。张伟先生因个人 原因申请辞去公司职工代表董事职务，辞任后仍在公司任职；杨磊先生因工作调 整申请辞去公司副总经理职务，辞任后仍在公司任职，经公司职工代表大会选举 其将担任公司职工代表董事。张伟先生和杨磊先生的前述辞任报告自送达公司董 事会之日起生效。 一、董事、高级管理人员离任情况 | 姓名 | 离任职务 | | 离任时间 | | 原定任期 | | 离任 | 是否继续在 上市公司及 | 具体职务 （如适 | 是否存在 未履行完 | | ...

Core Viewpoint - The AI medical sector experienced a decline of 0.66% on February 11, with QianYuan Pharmaceutical leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.35% [1]. Group 1: Market Performance - The closing price of QianYuan Pharmaceutical was 11.44, down by 4.67%, with a trading volume of 209,800 shares and a transaction value of 243 million [2]. - The AI medical sector saw a net outflow of 1.345 billion from major funds, while retail investors contributed a net inflow of 1.14 billion [2][3]. Group 2: Individual Stock Performance - YoukeDe (688158) closed at 37.54, up by 5.12%, with a trading volume of 631,000 shares and a transaction value of 2.36 billion [1]. - AidiTe (301580) closed at 55.18, up by 4.63%, with a trading volume of 46,100 shares and a transaction value of 251 million [1]. - SanNuo Biology (300298) closed at 18.54, up by 2.71%, with a trading volume of 105,200 shares and a transaction value of 194 million [1]. - The top decliners included QianYuan Pharmaceutical (300254) and KaiPu Biology (300639), with declines of 4.67% and 4.23%, respectively [2].

Group 1: Banking and Wealth Management - The scale of bank wealth management products has decreased by approximately 815 billion yuan, with 14 major wealth management companies managing a total of 24.59 trillion yuan as of the end of January 2026, marking a decline for the second consecutive month since reaching a peak in November 2025 [1][2] - Despite the decline, there is optimism in the industry as low fixed deposit rates and a large amount of fixed deposits maturing in 2026 may lead to a reallocation of household wealth towards wealth management products [1] - Sales of bank wealth management products surged before the Spring Festival, with some products breaking sales records, indicating a potential recovery in the market [1] Group 2: Private Equity and Investment - The number of domestic private equity firms managing over 10 billion yuan has reached a record high of 122, increasing by 10 from the end of December 2025 [1] - Eight new private equity firms entered the 10 billion yuan club in January 2026, showcasing a growing trend in the private equity sector [1] Group 3: Energy Market - The EIA's short-term energy outlook report predicts that Brent crude oil prices will average $58 per barrel in 2026, up from a previous estimate of $56 per barrel, while WTI crude oil prices are expected to average $53.42 per barrel, an increase from $52.21 per barrel [2] Group 4: Silver Market - The World Silver Association forecasts that the silver market will experience a supply deficit for the sixth consecutive year in 2026, with a projected shortfall of 67 million ounces [3] - Global silver demand is expected to remain stable, driven by robust retail investment, which may offset declines in other key demand areas such as jewelry and industrial use [3] Group 5: IPO Market - The Hong Kong IPO market has been active in 2026, with fundraising exceeding 79 billion HKD, representing a year-on-year increase of over 1220% [3][4] - As of February 10, 2026, 422 companies are queued for IPOs in Hong Kong, with over 100 having submitted applications since the beginning of the year [3] Group 6: Credit Card Industry - In 2025, 65 credit card centers were closed, surpassing the total number of closures from 2020 to 2024, indicating a significant contraction in the credit card industry [4] - The trend of closing credit card centers is spreading from state-owned and joint-stock banks to city commercial banks, reflecting a shift from expansion to competition in the credit card sector [4] Group 7: Corporate Actions - Ningde Times issued its first green technology innovation bond for 2026, raising 5 billion yuan with a coupon rate of 1.70% [6] - Huazhang Technology plans to acquire 100% of Huayi Microelectronics for 29.96 billion yuan, aiming to enhance its packaging and testing business in the semiconductor sector [10]

证券代码：688658 证券简称：悦康药业 公告编号：2026-004 悦康药业集团股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东会召开的时间：2026年2月6日 （二）股东会召开的地点：北京市北京经济技术开发区科创七街 11 号悦康创 新药物国际化产业园一楼 会议室。 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ （四）表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由公司董事会召集，董事长于伟仕先生主持，会议采用现场投票和网络投票相结合的表决方 式。本次股东会的召集和召开程序、出席会议人员的资格和召集人资格、会议的表决程序和表决结果均 符合《中华人民共和国公司法》及《悦康药业集团股份有限公司章程》等规定。 （五）公司董事和董事会秘书的列席情况 二、议案审议情况 （一）非累积投票议案 1、议案名称：关于公司20 ...

证券代码：688658 证券简称：悦康药业 公告编号：2026-004 悦康药业集团股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 2 月 6 日 （二） 股东会召开的地点：北京市北京经济技术开发区科创七街 11 号悦康创 新药物国际化产业园一楼会议室。 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 222 | | --- | --- | | 普通股股东人数 | 222 | | 2、出席会议的股东所持有的表决权数量 | 82,542,058 | | 普通股股东所持有表决权数量 | 82,542,058 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 18.5704 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 1 ...

tiantailaw.com 北京天驰君泰律师事务所 关于悦康药业集团股份有限公司 2026 年第一次临时股东会 的 法律意见书 北京市朝阳区北辰东路 8 号汇宾大厦 6 层（100101） | 北京 上海 广州 长春 南京 深圳 天津 郑州 成都 福州 珠海 武汉 | 北京市朝阳区北辰东路八号汇宾大厦 A 座六层 | | --- | --- | | 合肥 重庆 太原 苏州 宁波 杭州 济南 银川 沈阳 昆明 海口 无锡 | F6/A,North Star Huibin Plaza,No.8 Beichen East Road, Chaoyang District,Beijing 100101 China | T +8610 61848000 F +8610 61848000 tiantailaw.com 北京天驰君泰律师事务所 关于悦康药业集团股份有限公司 2026 年第一次临时股东会的法律意见书 致：悦康药业集团股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证 券法》等相关法律、行政法规，以及中国证券监督管理委员会发布的《上市公司股 东会规则》（2025 年修订）（ ...